09.20.21
A ginseng extract marketed by Farlong as NotoGinseng was evidenced in a recent placebo-controlled, triple-blind clinical trial to confer cardiovascular health benefits, when it was associated with a significant decrease in blood pressure and LDL cholesterol. The findings of the study, appearing in manuscript form in the journal Current Nutraceuticals, will be presented at the American Heart Association’s annual Science in Sessions 2021, which will be taking place both in-person in Boston and virtually. The abstract of the study will also be published in Circulation, AHA’s flagship scientific journal.
In the study, which was authored by Malkanthi Evans, Erin Lewis, David Crowley, Andy Zeng, Najla Guthrie, and Farlong CEO and executive director Jing Struve, involved 95 participants, who were either administered a daily placebo or Farlong NotoGinseng, in order to determine any significant changes in cholesterol or blood pressure, with health outcomes tracked from baseline to 12 weeks after supplementation in the participants.
Supplementation achieved significant average decreases in LDL-C by week 8, the authors noted, with a slight increase in HDL-C following 12 weeks of supplementation. Significantly more participants supplementing with the ginseng extract had improvements in all three cardiovascular disease risk factors (high LDL-C, systolic blood pressure, and low HDL-C) at a rate of 17.5%, compared to only 5% of those on placebo, at week 12.
According to the authors, there was a possibility that the participants would progress to a disease state based on their cardiovascular health parameters at baseline. “Even a small reduction in cholesterol is clinically meaningful in populations at risk for developing cardiovascular diseases,” Farlong noted in the announcement of the study.
“We are extremely proud that our manuscript was accepted for publication in Current Nutraceuticals based on the alignment of the manuscript with the journal’s aim, scope, and peer-review process,” Dr. Erin Lewis, lead scientist at KGK Science, said.
“This publication is a significant accomplishment as we are presenting a novel concept that has not been previously addressed in the nutraceutical industry,” Dr. Malkanthi Evans, chief scientific officer at KGK, added.
In the study, which was authored by Malkanthi Evans, Erin Lewis, David Crowley, Andy Zeng, Najla Guthrie, and Farlong CEO and executive director Jing Struve, involved 95 participants, who were either administered a daily placebo or Farlong NotoGinseng, in order to determine any significant changes in cholesterol or blood pressure, with health outcomes tracked from baseline to 12 weeks after supplementation in the participants.
Supplementation achieved significant average decreases in LDL-C by week 8, the authors noted, with a slight increase in HDL-C following 12 weeks of supplementation. Significantly more participants supplementing with the ginseng extract had improvements in all three cardiovascular disease risk factors (high LDL-C, systolic blood pressure, and low HDL-C) at a rate of 17.5%, compared to only 5% of those on placebo, at week 12.
According to the authors, there was a possibility that the participants would progress to a disease state based on their cardiovascular health parameters at baseline. “Even a small reduction in cholesterol is clinically meaningful in populations at risk for developing cardiovascular diseases,” Farlong noted in the announcement of the study.
“We are extremely proud that our manuscript was accepted for publication in Current Nutraceuticals based on the alignment of the manuscript with the journal’s aim, scope, and peer-review process,” Dr. Erin Lewis, lead scientist at KGK Science, said.
“This publication is a significant accomplishment as we are presenting a novel concept that has not been previously addressed in the nutraceutical industry,” Dr. Malkanthi Evans, chief scientific officer at KGK, added.
